CyclinD-CDK4/6 Complexes Phosphorylate CDC25A and Regulate Its Stability

Overview

Journal Oncogene

Specialties Molecular Biology
Oncology

Date 2017 Feb 14

PMID 28192398

Citations 20

Authors

C Dozier

L Mazzolini

C Cenac

C Froment

O Burlet-Schiltz

A Besson

S Manenti

Affiliations

Soon will be listed here.

Abstract

The phosphatase CDC25A is a key regulator of cell cycle progression by dephosphorylating and activating cyclin-CDK complexes. CDC25A is an unstable protein expressed from G1 until mitosis. CDC25A overexpression, which can be caused by stabilization of the protein, accelerates the G1/S and G2/M transitions, leading to genomic instability and promoting tumorigenesis. Thus, controlling CDC25A protein levels by regulating its stability is a critical mechanism for timing cell cycle progression and to maintain genomic integrity. Herein, we show that CDC25A is phosphorylated on Ser40 throughout the cell cycle and that this phosphorylation is established during the progression from G1 to S phase. We demonstrate that CyclinD-CDK4/CDK6 complexes mediate the phosphorylation of CDC25A on Ser40 during G1 and that these complexes directly phosphorylate this residue in vitro. Importantly, we also find that CyclinD1-CDK4 decreases CDC25A stability in a ßTrCP-dependent manner and that Ser40 and Ser88 phosphorylations contribute to this regulation. Thus our results identify cyclinD-CDK4/6 complexes as novel regulators of CDC25A stability during G1 phase, generating a negative feedback loop allowing control of the G1/S transition.

Citing Articles

DNA Damage-Induced Ferroptosis: A Boolean Model Regulating p53 and Non-Coding RNAs in Drug Resistance.

Gupta S, Silveira D, Mombach J, Hashimoto R Proteomes. 2025; 13(1.

PMID: 39846637 PMC: 11755436. DOI: 10.3390/proteomes13010006.

TOP2A modulates signaling via the AKT/mTOR pathway to promote ovarian cancer cell proliferation.

Zhang K, Zheng X, Sun Y, Feng X, Wu X, Liu W Cancer Biol Ther. 2024; 25(1):2325126.

PMID: 38445610 PMC: 10936659. DOI: 10.1080/15384047.2024.2325126.

Cyclin A-CDK1 suppresses the expression of the CDK1 activator CDC25A to safeguard timely mitotic entry.

Ng L, Ma H, Poon R J Biol Chem. 2023; 299(3):102957.

PMID: 36717077 PMC: 9986519. DOI: 10.1016/j.jbc.2023.102957.

Azelnidipine inhibits esophageal squamous cell carcinoma proliferation and by targeting MEK1/2.

Zhao L, Zhang Y, Li A, Lu X, Li M, Yuan Q Mol Ther Oncolytics. 2022; 27:61-72.

PMID: 36284716 PMC: 9574346. DOI: 10.1016/j.omto.2022.09.007.

MAP9 Exhibits Protumor Activities and Immune Escape toward Bladder Cancer by Mediating TGF-1 Pathway.

Zhang C, Han B, Guo Y, Guan H, Chen Z, Liu B J Oncol. 2022; 2022:3778623.

PMID: 35656338 PMC: 9155934. DOI: 10.1155/2022/3778623.

References

Hoffmann I, Draetta G, Karsenti E . Activation of the phosphatase activity of human cdc25A by a cdk2-cyclin E dependent phosphorylation at the G1/S transition. EMBO J. 1994; 13(18):4302-10. PMC: 395357. DOI: 10.1002/j.1460-2075.1994.tb06750.x. View

Ducruet A, Lazo J . Regulation of Cdc25A half-life in interphase by cyclin-dependent kinase 2 activity. J Biol Chem. 2003; 278(34):31838-42. DOI: 10.1074/jbc.M303604200. View

Fernandez-Vidal A, Mazars A, Manenti S . CDC25A: a rebel within the CDC25 phosphatases family?. Anticancer Agents Med Chem. 2008; 8(8):825-31. DOI: 10.2174/187152008786847684. View

Watanabe H, Pan Z, Schreiber-Agus N, DePinho R, Hurwitz J, Xiong Y . Suppression of cell transformation by the cyclin-dependent kinase inhibitor p57KIP2 requires binding to proliferating cell nuclear antigen. Proc Natl Acad Sci U S A. 1998; 95(4):1392-7. PMC: 19016. DOI: 10.1073/pnas.95.4.1392. View

Chung J, Bunz F . Cdk2 is required for p53-independent G2/M checkpoint control. PLoS Genet. 2010; 6(2):e1000863. PMC: 2829054. DOI: 10.1371/journal.pgen.1000863. View

Kittipatarin C, Li W, Bulavin D, Durum S, Khaled A . Cell cycling through Cdc25A: transducer of cytokine proliferative signals. Cell Cycle. 2006; 5(9):907-12. DOI: 10.4161/cc.5.9.2693. View

Honaker Y, Piwnica-Worms H . Casein kinase 1 functions as both penultimate and ultimate kinase in regulating Cdc25A destruction. Oncogene. 2010; 29(23):3324-34. PMC: 2883652. DOI: 10.1038/onc.2010.96. View

Busino L, Donzelli M, Chiesa M, Guardavaccaro D, Ganoth D, Dorrello N . Degradation of Cdc25A by beta-TrCP during S phase and in response to DNA damage. Nature. 2003; 426(6962):87-91. DOI: 10.1038/nature02082. View

Hutchins J, Clarke P . Many fingers on the mitotic trigger: post-translational regulation of the Cdc25C phosphatase. Cell Cycle. 2003; 3(1):41-5. View

10.

Ray D, Terao Y, Nimbalkar D, Hirai H, Osmundson E, Zou X . Hemizygous disruption of Cdc25A inhibits cellular transformation and mammary tumorigenesis in mice. Cancer Res. 2007; 67(14):6605-11. DOI: 10.1158/0008-5472.CAN-06-4815. View

11.

Timofeev O, Cizmecioglu O, Settele F, Kempf T, Hoffmann I . Cdc25 phosphatases are required for timely assembly of CDK1-cyclin B at the G2/M transition. J Biol Chem. 2010; 285(22):16978-90. PMC: 2878026. DOI: 10.1074/jbc.M109.096552. View

12.

Isoda M, Kanemori Y, Nakajo N, Uchida S, Yamashita K, Ueno H . The extracellular signal-regulated kinase-mitogen-activated protein kinase pathway phosphorylates and targets Cdc25A for SCF beta-TrCP-dependent degradation for cell cycle arrest. Mol Biol Cell. 2009; 20(8):2186-95. PMC: 2669026. DOI: 10.1091/mbc.e09-01-0008. View

13.

Ray D, Terao Y, Fuhrken P, Ma Z, DeMayo F, Christov K . Deregulated CDC25A expression promotes mammary tumorigenesis with genomic instability. Cancer Res. 2007; 67(3):984-91. DOI: 10.1158/0008-5472.CAN-06-3927. View

14.

Boutros R, Dozier C, Ducommun B . The when and wheres of CDC25 phosphatases. Curr Opin Cell Biol. 2006; 18(2):185-91. DOI: 10.1016/j.ceb.2006.02.003. View

15.

Bhowmick N, Ghiassi M, Aakre M, Brown K, Singh V, Moses H . TGF-beta-induced RhoA and p160ROCK activation is involved in the inhibition of Cdc25A with resultant cell-cycle arrest. Proc Natl Acad Sci U S A. 2003; 100(26):15548-53. PMC: 307605. DOI: 10.1073/pnas.2536483100. View

16.

Fernandez-Vidal A, Ysebaert L, Didier C, Betous R, De Toni F, Prade-Houdellier N . Cell adhesion regulates CDC25A expression and proliferation in acute myeloid leukemia. Cancer Res. 2006; 66(14):7128-35. DOI: 10.1158/0008-5472.CAN-05-2552. View

17.

Chang K, Vincent F, Shah K . Deregulated Cdk5 triggers aberrant activation of cell cycle kinases and phosphatases inducing neuronal death. J Cell Sci. 2012; 125(Pt 21):5124-37. DOI: 10.1242/jcs.108183. View

18.

Jin J, Shirogane T, Xu L, Nalepa G, Qin J, Elledge S . SCFbeta-TRCP links Chk1 signaling to degradation of the Cdc25A protein phosphatase. Genes Dev. 2003; 17(24):3062-74. PMC: 305258. DOI: 10.1101/gad.1157503. View

19.

Kanemori Y, Uto K, Sagata N . Beta-TrCP recognizes a previously undescribed nonphosphorylated destruction motif in Cdc25A and Cdc25B phosphatases. Proc Natl Acad Sci U S A. 2005; 102(18):6279-84. PMC: 1083676. DOI: 10.1073/pnas.0501873102. View

20.

Lim K, Chew K, Tan J, Wang C, Chung K, Zhang Y . Parkin mediates nonclassical, proteasomal-independent ubiquitination of synphilin-1: implications for Lewy body formation. J Neurosci. 2005; 25(8):2002-9. PMC: 6726069. DOI: 10.1523/JNEUROSCI.4474-04.2005. View